Thromboembolic disorders are major causes of morbidity and mortality. It is well-recognised that the pathogenesis is different for arterial and venous thrombosis; however, both involve coagulation activation. Anticoagulants are used for the prevention and treatment of a wide variety of thromboembolic and related conditions. Agents with anti- inflammatory properties in addition to anticoagulatio...

Peripheral blood hypereosinophilia reflects various underlying disorders. However, its thromboembolic consequences are not often highlighted. We report a case of acute pulmonary embolism in a 42 year-old male prisoner hospitalized for erythrodermic psoriasis who presented with generalized edema and shortness of breath. Severe eosinophilia (absolute eosinophil count 6232/ΜL) was also noted. Alth...

The key reason behind the success of heparin in thrombosis and beyond is its polypharmacological sites of action for the prevention and treatment of multifactorial diseases that will only benefit slightly with single pharmacological mechanism-based agents. Thromboembolic disorders are driven by hypercoagulable, hyperactive platelet, proinflammatory, endothelial dysfunction, and proangiogenesis ...

OBJECTIVE Thromboembolic disorders are leading causes of morbidity and mortality, with treatment and prophylaxis a priority. There has been a heavy dependency upon warfarin and heparin for anticoagulation for 60 years. This is likely to change with the emergence of novel oral anticoagulants. CONCLUSION Interventional radiologists are increasingly encountering these medications, and a thorough...

Neonatal thromboembolic events, both arterial and venous, are rare but increasingly recognised problems in tertiary care neonatology. The pathophysiology of these events in the context of the neonatal haemostatic system and the importance of both inherited and acquired prothrombotic disorders remain poorly defined. Similarly, optimal diagnostic and therapeutic approaches in this setting are not...

Acquired thrombotic and thromboembolic disorders may be presented initially with symptoms and signs of acute ischaemia or organ dysfunction that will lead many of these patients to seek care in the emergency department. We report a case of a 19-year-old female patient who developed catastrophic antiphospholipid syndrome (CAPS syndrome or Asherson syndrome) 6 weeks post stillbirth with an initia...

Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabi...

BACKGROUND Although the platelet count does not correlate with the rate of thrombosis, there is evidence that a strict control of the platelet count decreases the incidence of thromboembolic complications in essential thrombocythemia. In the current study, the authors evaluated the efficacy and tolerability of anagrelide in thrombocytosis associated with myeloproliferative disorders. METHODS ...

Abstract Context A higher incidence of thromboembolic disorders in COVID-19 has been reported by many clinicians worldwide. Objective, design and data sources Selected studies found PubMed that events were included for meta-analysis using weighted fixed random effects. Data from 19 articles on cohort patients diagnosed with events, including thrombosis embolism this review. Results The likeliho...